Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PHIO PHARMACEUTICALS CORP.

(PHIO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp, formerly RXi Pharmaceuticals Corporation, is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) (sd-rxRNA) therapeutic platform. The Company’s focuses on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intratumoral injection. The Company’s pipeline include RXI-762 and RXI-804. Its sd-rxRNA compounds are designed to down-regulate the expression of a specific gene that may be over-expressed in a disease condition. The Company is developing RXI-762 for the treatment of Melanoma, Ovarian cancer and other indications. RXI-804 is an sd-rxRNA compound that is designed to suppress the expression of immune checkpoint protein, TIGIT.

Number of employees : 10 people.
Sales per Business
20192020Delta
Immuno-oncology Therapeutics0.02100%---
USD in Million
Sales per region
20192020Delta
United States0.02100%---
USD in Million
Managers
Name Title Age Since
Gerrit Dispersyn, Dr. President, Chief Executive Officer & Director 45 2019
Caitlin Kontulis Secretary, VP-Finance & Administration - -
Simon Fricker, Dr. Vice President-Research - 2019
James Cardia, Dr. Vice President-Business Operations - 2017
Robert J. Bitterman Chairman 69 2013
H. Paul Dorman Independent Director 83 2013
Curtis A. Lockshin, Dr. Independent Director 59 2013
Jonathan E. Freeman, Dr. Independent Director 52 2017
Robert L. Ferrara Independent Director 69 2019
Members of the board
Name Title Age Since
Robert J. Bitterman Chairman 69 2013
Geert Cauwenbergh, Dr. Director 66 2019
H. Paul Dorman Independent Director 83 2013
Curtis A. Lockshin, Dr. Independent Director 59 2013
Gerrit Dispersyn, Dr. President, Chief Executive Officer & Director 45 2019
Jonathan E. Freeman, Dr. Independent Director 52 2017
Robert L. Ferrara Independent Director 69 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 13,534,389 13,495,345 99.7% 0 0.0% 99.7%
Shareholders
NameEquities%
Empery Asset Management LP 899,684 6.65%
Heights Capital Management, Inc. 360,094 2.66%
Armistice Capital LLC 240,592 1.78%
GSA Capital Partners LLP 132,333 0.98%
The Vanguard Group, Inc. 122,697 0.91%
Gerrit Dispersyn 89,281 0.66%
Geode Capital Management LLC 87,501 0.65%
Caitlin Kontulis 39,826 0.29%
Dimensional Fund Advisors LP 34,808 0.26%
Wedbush Securities, Inc. (Investment Management) 33,374 0.25%
Company contact information
Phio Pharmaceuticals Corp.
257 Simarano Drive
Suite 101
Marlborough, MA 01752

Phone : +1.508.767.3861
Fax : +1.508.767.3862
Web : http://www.phiopharma.com
Sector Other Biotechnology & Medical Research
Connections : Phio Pharmaceuticals Corp.